Section Review Cardiovascular & Renal: Recent advances in the pharmacology and therapeutic potential of potassium channel openers

References

• HAMILTON TC, WEIR SW, WESTON AFL Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br. J. Pharmacol. (1986) 88:103–111.
   PubMed Web of Science ®Google Scholar
• EDWARDS G, WESTON AH: The pharmacology of potas-sium channel superfamllie" s: modulation of !Caw and BKca. In: Molecular and Cellular Mechanisms of Cardiovas-cular Regulation, Endoh M, Morad M, Scholz H, Iijima T (Eds.), Springer, Tokyo 0990:93–109.
   Google Scholar
• MILLER C: The charylbdotoxin family of le channel-blocking peptides. Neuron (1995) 15:5–10.
   PubMed Web of Science ®Google Scholar
• RUDY B: Diversity and ubiquity of K channels. Neurosci-ence (1988) 25:729–749.
   PubMed Web of Science ®Google Scholar
• GUTMAN GA, CHANDY KG: Nomenclature of mammal-ian-dependent potassium channel genes. Sem. Neurosci. (1993) 5:101–106.
   Google Scholar
• CHANDY KG, GUTMAN GA: Voltage-gated potassiumchannel genes. In: Handbook of Receptors, and Channels.. Ligand- and Voltage-Gated Ion Channels. North RA (Ed.), CRC Press, Inc., Boca Raton (1995):1–71.
   Google Scholar
• ISOM LL, DE JONGH KS, CATTERALL WA: Auxiliarysubunits of voltage-gated ion channels. Neuron (1994) 12:1183–1194.
   PubMed Web of Science ®Google Scholar
• PONGS 0: Regulation of the activity of voltage-gatedpotassium channels by jI subunits. Semin. Neurosci. (1995) 7:137–146.
   Google Scholar
• INAGAKI N, GONOI T, CLEMENT JP et al.: Reconstitution of IKATp: an inward rectifier subunit plus the sulfonyl-urea receptor. Science (1995) 270:1166–1170.
   PubMed Web of Science ®Google Scholar
• AMMAIÄ C, MOORHOUSE A, GRIBBLE F et al.: Promiscu-ous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels. Nature (1996) 379:545–548.
   PubMed Web of Science ®Google Scholar
• INAGAKI N, GONOI T, CLEMENT JP et al.: A family ofsulfonylurea receptors determines the pharmacologi-cal properties of ATP-sensitive IC channels. Neuron (1996) 16:1011–1017.
   PubMed Web of Science ®Google Scholar
• HIGGINS CF: The ABC of channel regulation_ Cell (1995)82:693–696.
   Google Scholar
• VAN KUIJCK MA, VAN AUBEL RAMII, BUSCH AE et al.:Molecular cloning and expression of a cyclic AMP-acti-vated chloride conductance regulator: a novel ATP-binding cassette transporter. Proc. Natl. Acad. Sci. USA (1996) 93:5401–5406.
   PubMed Web of Science ®Google Scholar
• SAH P: Ca2tactivated IC currents in neurones: types,physiological roles and modulation. Trends Neurosci. (1996) 19:150–154.
   PubMed Web of Science ®Google Scholar
• SMALL RC, ISAAC LM, MCARDLE S, POCOCK TM: Relaxa-tion of airways smooth musde induced by agonists at beta-adrenoceptors: signal transduction pathways and role of plasmalemmal Ktchannel opening. In: Sym-pathomimetic Enantiomers in the Treatment of Asthma. Costello J (Ed.), Parthenon Publishing, London (1996):11–41.
   Google Scholar
• EVANS JM, STEMP G: Structure-activity relationships of benzopyran based potassium channel activators. In: Potassium Channels and their Modulators. Evans JM, Ham-ilton TC, Longman SD, Stemp G (Eds.), Taylor & Francis, Basingstoke (1996):27–55.
   Google Scholar
• EDWARDS G, WESTON AH: Structure-activity relation-ships of IC channel openers. Trends Pharmacol. Sci. (1990) 11:417–422.
   PubMed Web of Science ®Google Scholar
• PALFREYMAN MN: Syntheses and structure-activity rela-tionships of pyridine based potassium channel activa-tors. In: Potassium Channels and their Modulators. Evans JM, Hamilton TC, Longman SD, Stemp G (Eds.), Taylor & Francis, Basingstoke (1996):57–77.
   Google Scholar
• ATWAL KS: Advances in the structure-activity relation-ships, mechanisms of action, and therapeutic utilities of ATP-sensitive potassium channel openers. Drug De-velop. Res. (1994) 33:250–262.
   Web of Science ®Google Scholar
• EDWARDS G, WESTON AH: The pharmacology of ATP- sensitive potassium channels. Ann. Rev. Pharmacol. Toxi-col. (1993) 33:597–637.
   PubMed Web of Science ®Google Scholar
• PANTEN U, SCHWANSTECHER M, SCHWANSTECHER C: Sulfonylurea receptors and mechanism of sulfonylurea action. Exp. Clin. Endocrinol. (1996) 104:1–9.
   Google Scholar
• GOPALAKRISHNAN M, JOHNSON DE, JANIS RA, TRIGGLEDJ: Characterization of binding of the ATP-sensitive potassium channel ligand, [3111glyburide, to neuronal and muscle preparations. J. Pharmacol. Exp. Ther. (1991) 257:1162–1171.
   PubMedGoogle Scholar
• ZINI S, BEN-ART Y, ASHFORD MU: Characterization ofsulfonylurea receptors and the action of potassium channel openers on choblnergk neurotransmission in guinea pig isolated small intestine. J. Pharmacol. Exp. Ther. (1991) 259:566–573.
   PubMed Web of Science ®Google Scholar
• NIKI I, ASHCROFT SJH: Possible involvement of protein phosphorylation in the regulation of the sulphony-lurea receptor of a pancreatic beta-cell line, HIT-T15. Biochim. Biophys. Acta (1991) 1133:95–101.
   PubMed Web of Science ®Google Scholar
• SCHWANSTECHER M, BRANDT C, BEHRENDS S etal.: Effect of MgATP on pinaddil-induced displacement of gliben-clamide from the sulphonylurea receptor in a pancre-atic 13-cell line and rat cerebral cortex. Br. J. Pharmacol. (1992) 106:295–301.
   Google Scholar
• BRAY KM, QUAST U: A specific binding site for IC* channel openers in rat aorta. J. Biol. Chem. (1992) 267:11689–11692.
   PubMed Web of Science ®Google Scholar
• QUAST U, BRAY KM, ANDRES H etal.: Binding of the lechannel opener [311]1075 in rat isolated aorta - rela-tionship to functional effects of openers and blockers. Mol. Pharmacol. (1993) 43:474–481.
   Google Scholar
• INOUE I, NAGASE H, KISHI K, HEGUTI T: ATP-sensitive lechannel in the mitochondrial inner membrane. Nature (1991) 352:244–247.
   PubMed Web of Science ®Google Scholar
• GARLID KD, PAUCEK P, YAROV-YAROVOY V, SUN X. SCHINDLER PA: The mitochondrial ICATp channel as a receptor for potassium channel openers. J. Biol. Chem. (1996) 271:8796–8799.
   Google Scholar
• OZANNE SE, GUEST PC, HUTTON JC, HALES CN: Intracel-lular localization and molecular heterogeneity of the sulphonylurea receptor in insulin-secreting cells. Dia-betologia (1995) 38:277–282.
   Google Scholar
• GROVER GJ, ATWAL KS: BMS-180448, a glyburide-revers-ible cardioprotective agent with minimal vasodilator activity. Cardiovasc. Drug Rev. (1995) 13:123–136.
   Google Scholar
• HUNNICUTT EJ, DAVIS JN, CHISHOLM JC: A new gliben-clamide-insensitive neuroselective hyperpolarizing agent. Eur. J. Pharmacol. (1994) 261:R1–R3.
   PubMed Web of Science ®Google Scholar
• MCKAY MC, DWORETSKY SI, MEANWELL NA et al.: Open-ing of large-conductance calcium-activated potassium channels by the substituted benzinuldazolone NS004. J. Neurophysiol. (1994) 71:1873–1882.
   PubMed Web of Science ®Google Scholar
• OLESEN S-P: Activators of large-conductance Ca2+-de-pendent IC channels. Exp. Opin. Invest. Drugs (1994) 3:1181–1188.
   Google Scholar
• DWORETZKY SI, TROJNACKI JT GRIBKOFF VK: Cloningand expression of a human large-conductance calcium-activated potassium channeL Mol. Brain. Res. (1994) 27:189–193.
   Web of Science ®Google Scholar
• EDWARDS G, NIEDERSTE-HOLLENBERG A, SCHNEIDER J, NOACK T, WESTON AH: Ion channel modulation by NS 1619, the putative BK-Ca channel opener, in vascular smooth muscle. Br. J. Pharmacol. (1994) 113:1538–1547.
   PubMed Web of Science ®Google Scholar
• GRIBKOFF VK, CHAMPIGNY G, BARBRY P et al.: The substituted benzitnidazolone NS004 is an opener of the cystic fibrosis chloride channeL J. Biol. Chem. (1994) 269:10983–10986.
   Web of Science ®Google Scholar
• OTTOLIA M, TORO L: Potentiation of large conductance Kca channels by niflumic, flufenarnic, and mefenamk adds. Biophys. J. (1994) 67:2272–2279.
   PubMed Web of Science ®Google Scholar
• GREENWOOD IA, LARGE WA. Comparison of the effects of fenamates on Ca-activated chloride and potassium currents in rabbit portal vein smooth muscle cells. Br. Pharmacol. (1995) 116:2939–2948.
   PubMed Web of Science ®Google Scholar
• K1RKUP AJ, EDWARDS G, WESTON AEI: Investigation of the effects of 5-nitro-2-(3-phenylpropylamino)-benzok add (NPPB) on membrane currents in rat portal vein. Br. J. Pharmacol. (1996) 117:175–183.
   PubMed Web of Science ®Google Scholar
• WALLNER M, MEERA P, OTTOLIA M etal.: Characterization of and modulation by a P-subunit of a human maxi 1Cca channel cloned from myometriu.m. Receptors Channels (1995) 3:185–199.
   Google Scholar
• MCMANUS OB, HARRIS GH, GIANGIAGOMO KM etal.: Anactivator of calcium-dependent potassium channels Isolated from a medicinal herb. Biochemistry (1993) 32 :6128–6133.
   Google Scholar
• SINGH SB, GOETZ MA, ZINK DL etal.: Maxiltdiol a novel dihydroxyisoprimane as an agonist of maxi-K than-nels. J. Chem. Soc. Perkin Trans. (1994) 1:3349–3352.
   Google Scholar
• LEE SI-I, HENSENS OD, HELMS GL etal.: L-735,334, a novel sesquiterpenoid potassium channel-agonist from Tricbodernsa virens. J. Nat. Prod. (1995) 58:1822–1828.
   Google Scholar
• KACZOROWSKI GJ, KNAUS HG, LEONARD RJ, MCMANUS OB, GARCIA ML: High-conductance calcium-activated potassium channels; structure, pharmacology, and function. J. Bioenerg. Biomernbr. (1996) 28:255–267.
   PubMed Web of Science ®Google Scholar
• MCMANUS OB, HELMS LMII, PALLANCK L etal.: Functional role of the 13 subunit of high conductance calcium-acti-vated potassium channels. Neuron (1995) 14:645–650.
   Google Scholar
• COLATSKY TJ, HAMILTON TC: Potassium channel modu-lators: clinical experiences and future prospects. In: Potassium Channels and their Modulators. Evans JM, Ham-ilton TC, Longman SD, Stemp G (Eds.), Taylor & Francis, Basingstoke (1996):383–411.
   Google Scholar
• HERDON H: Potassium channel modulators and the central nervous system. In: Potassium Channels and their Modulators. Evans JM, Hamilton TC, Longman SD, Stemp G (Eds.), Taylor & Francis, Basingstoke (1996):361–382.
   Google Scholar
• NIELSEN-KUDSK JE, BOESGAARD S, ALDERSHVILE J: channel opening: a new drug principle in cardiovascu-lar medicine. Heart (1996) 76:109–116.
   PubMed Web of Science ®Google Scholar
• SMALL RC, FOSTER RW: Potassium channel openers as anti-asthma drugs. In: Allergy and Allergic Diseases. Kay AB (Ed.), Blackwell Science, Oxford (1996):605–614.
   Google Scholar
• FRIEDEL HA, BROGDEN RN: Pinacidil: a review of its pharmacological and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs (1990) 39:929–967.
   PubMed Web of Science ®Google Scholar
• FLETCHER AE, BATTERSBY C, ADNITT P et al.: Quality of life on antihypertensive therapy: a double-blind trial comparing quality of life on pinacidil and nifedipine In combination with a thiazide diuretic. J. Cardiovasc. Pharmacol. (1992) 20:108–114.
   PubMed Web of Science ®Google Scholar
• FRAMPTON J, BUCKLE MM, FITTON A: Nieorandil - a review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs (1992) 44:625–655.
   PubMed Web of Science ®Google Scholar
• PARRATT JR, KANE KA: KA•rp channels in ischaemic preconditioning. Cardiovasc. Res. (1994) 28:783–787.
   PubMed Web of Science ®Google Scholar
• GROSS GJ: Cardioprotective properties of potassium channel modulators. In: Potassium Channels and their Modulators. Evans JM, Hamilton TC, Longman SD, Stemp G (Eds.), Taylor & Francis, Basingstoke (1996):257–273.
   Google Scholar
• BOWRING NE, ARCH JRS, BUCKLE DR, TAYLOR JF: Com-parison of the airways relaxant and hypotensive poten-cies of the potassium channel activators BRL-55834 and levcroinakalira (BRL-38227) in vivo in guinea-pigs and rats. Br. J. Pharmacol. (1993) 109:1133–1139.
   PubMed Web of Science ®Google Scholar
• ARCH JRS: Potassium channel activators: airway phar-macology and bronchial asthma. In: Potassium Channels and their Modulators. Evans JM, Hamilton TC, Longman SD, Stemp G (Eds.), Taylor & Francis, Basingstoke (1996):275–302.
   Google Scholar
• CHAPMAN ID, KRISTERSSON A, MATHELIN G et al.: Effectsof a potassium channel opener (SDZ PCO 400) on guinea-pig and human pulmonary airways. Br. J. Phar-macol. (1992) 106:423–429.
   PubMed Web of Science ®Google Scholar
• PACIOREK PM, SPENCE AM, GATER PR, WATERFALL JF:PAF-induced hyperreactivity in the guinea-pig is inhib-ited by Ro 31–6930 and salineteroL In: New Concepts in Asthma. Tarayre JP, Vargaftig BB, Carina E (Eds.), Macmillan Press, London (1993):299.
   Google Scholar
• MORLEY J: IC channel openers and suppression of airway hyperreactivity. Trends Pharmacol. Sci. (1994) 15:463–468.
   PubMed Web of Science ®Google Scholar
• BUCHHEIT K-H, HOFMANN A: KATI, channel openersreverse immune complex-induced airways hyperreac-tivity independently of smooth muscle relaxation. Naunyn-Schmiedeberg's Arch. Pharmacol. (1996) 354:355–361.
   Google Scholar
• ANDERSSON K-E, ANDERSSON P-0, FOVAEUS M et al.:Effects of pinacidil on bladder muscle. Drugs (1988) 36:41–49.
   Google Scholar
• MALMGREN A, ANDERSSON K-E, SJOGREN C, ANDERSSONPO: Effects of pinacidil and cromakalim (BRL 34915) on bladder function in rats with detrusor instability. J. Urol. (1989) 142:1134–1138.
   PubMed Web of Science ®Google Scholar
• FOSTER CD, SPEAKMAN MJ, FUJII K, BRADING AF: The effects of cromakalim on the detrusor muscle of human and pig urinary bladder. Br. J. Urol. (1989) 63:284–294.
   PubMedGoogle Scholar
• EDWARDS G, HENSHAW M, MILLER M, WESTON AH: Comparison of the effects of several potassium-channel openers on rat bladder and rat portal vein in vitro. Br, J. Pharmacol. (1991) 102:679–686.
   PubMed Web of Science ®Google Scholar
• GRANT TL, OHNMACHT CJ, HOWE BB: Anilide tertiarycarbinols: a novel series of K. channel openers. Trends Pharmacol. Sci. (1994) 15:402–404.
   PubMed Web of Science ®Google Scholar
• HOWE BB, HALTERMAN TJ, YOCHIM CL et al.: ZENECAZD6169: a novel KATp channel opener with in vivo selectivity for urinary bladder. J. Pharmacol. Exp. Ther. (1995) 274:884–890.
   PubMed Web of Science ®Google Scholar
• LI JF1, YASAY GD, KAU ST et al.: Studies of the ICArp channel opening activity of the new dihydropyridine compound 9-(3-Cyanopheny1)-3,4,6,7,9,10-hexahydro-1,8-(2H,5H)-acridinedione in bladder detrusor in vitro. Arzneim.- Foisch. (1996) 46:525–530.
   Google Scholar
• LENTERS JB, MUSCHALEK-LETINA V, NLEMERS E et al.: Enantiomer, (-)-N-(2-Ethoxypheny1)-N'-(1,2,2-tri-methylpropy0-2-nitromethen-1,1-diamin, Verfahren zu dessen Herstellung und Verwendung desselhen. EP0561237A2 (1993).
   Google Scholar
• BLACKBURN TP, BUCKINGHAM RE, CHAN WN et al.: Stereochemical differentiation of anticonvulsant and antihypertensive effects in 4-(fluorobenzoylamino)-benzopyrans. Bioorg. Med. Chem. Lett. (1995) 5:1163–1166.
   Web of Science ®Google Scholar
• KNIGHT C, PURCELL H, FOX K: Potassium channel open-ers: clinical applications in ischernic heart disease - overview of clinical efficacy of nicorandiL Cardiovasc. Drug Ther. (1995) 9:229–236.
   Google Scholar
• GOLDSTEIN SAN, COLATSKY TJ: Ion channels: too com-plex for rational drug design. Neuron (1996) 16:913–919.
   PubMed Web of Science ®Google Scholar